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Cytokine gene polymorphisms in preeclampsia
and eclampsia
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Camila S Franchim2 and Silvia Daher2
The clinical spectrum of preeclampsia (PE) ranges from mild hypertension to severe vasospasm associated with convulsions and
multiple organ damage. The biological factors that determine the progression of PE to eclampsia (E) are unknown. Endothelial
cell activation seems related to an impaired maternal immune response. The production of cytokines, IL-10 and TGF-b1, is
apparently suppressed, and altered IL-2/IL-10 and TNF-a/IL-10 ratios have been reported in preeclamptic cases. The
relationship between PE and cytokine gene polymorphism has been studied, but there are few studies that include eclamptic
patients. This study aimed at investigating whether polymorphisms in genes, TNF-a promoter (308 G4A), IL6 promoter (174
G4C), IFN-c intron 1 (+874 A4T), IL10 promoters (1082 A4G), (819 C4T) and (592 C4A) and TGF-b1 codon 10
(+869 T4C) and codon 25 (+915 G4C) are associated with E and/or PE. Genotyping was carried out in 266 Mulatto women
from the northeastern region of Brazil who were referred to a single maternity hospital: 92 with PE, 73 with E and 101
normotensive controls. The v2 or Fisher’s exact tests were used to compare genotype frequencies. Among the six single-
nucleotide polymorphisms (SNPs) studied, we found no difference in genotype frequencies between the groups. There was
a higher frequency of IFN-c (+874 A) in eclamptic patients in comparison with that in controls. (70.3 vs. 57.8%, respectively;
P¼0.02). There were no other significant differences in allelic frequencies between eclamptic, preeclamptic and control groups
We found no independent association between any single SNP and PE or E risk in this population of Mulatto women from the
northeastern region of Brazil.
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INTRODUCTION
Preeclampsia (PE) is a common systemic obstetric disorder and a
major cause of maternal and neonatal morbidity and mortality. The
clinical spectrum of PE is large, ranging from mild hypertension with
minimal proteinuria to severe hypertension associated with convulsions
and multiple end-organ damage that can lead to maternal demise.1
Current knowledge suggests that the underlying physiopathology
for eclampsia (E) is a posterior reversible encephalopathy syndrome
with vasogenic edema because of hyperfusion rather than vasospasms.2
The biological factors that determine the progression of PE to E
are unknown. General endothelial cell activation is present in both
conditions, and seems to be related to an impaired maternal immune
response.3
Excessive innate activity and a shift toward an inflammatory
cytokine profile have been reported in PE.4,5 Elevated levels of
Th-1 cytokines, such as tumor necrosis factor TNF-a, IFN-g and
low IL-4 production by phytohemagglutinin-stimulated peripheral
blood mononuclear cells have been identified in preeclamptic
patients. The production of immunoregulatory cytokines, IL-10 and
TGF-b1, is apparently suppressed, and altered IL-2/IL-10 and
TNF-a/IL-10 ratios have been reported in placental tissue from
preeclamptic cases.6
Cytokine gene polymorphisms have been associated with certain
inflammatory and infectious diseases, including some obstetric dis-
orders.7–10 The relationship between PE and single-nucleotide poly-
morphisms (SNPs) in cytokine genes has been investigated, but is still
unclear.11–15
The controversial results reported by different investigators may in
part be because of selection criteria. Genotype frequencies of SNPs and
linkage disequilibrium patterns can differ among ethnic groups,
leading to different results.16 Moreover, distinct clinical patterns may
involve different pathological mechanisms.17,18 Few studies have
evaluated patients with E.
Considering that cytokine gene polymorphism may influence dis-
ease susceptibility, severity and outcome,7,19,20 our purpose was to
investigate whether polymorphisms in genes, TNF-a promoter (308
G4A), IL6 promoter (174 G4C), IFN-g intron 1 (+874 A4T),
IL10 promoters (1082 A4G), (819 C4T) and (592 C4A) and
TGF-b1 codon 10 (+869 T4C) and codon 25 (+915 G4C) are
associated with E and/or PE in a northeastern Brazilian population.
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METHODS
All patients were Mulatto (of mixed white and black ancestry) and lived in the
same geographical location (Maceio, Alagoas, Brazil). All women with a single
live pregnancy and who were referred to a single hospital (Santa Monica
Obstetric Clinic) were eligible.
This case–control study included 92 women with PE, 73 patients with E and
101 healthy women (control). The control women had to be normotensive in
the index pregnancy, with a history of at least one previous normal pregnancy,
without any maternal or fetal disorder.
The diagnoses of PE and E were based on the criteria of the Report of the
‘National High Blood Pressure Education Program.’21
Exclusion criteria were multiple gestation, fetal death, autoimmune disease,
diabetes, uterine malformation, in vitro fertilization treatment, placental
abruption, any infection, cancer or any other systemic disease, including
preexisting hypertension.
On admission, 5 ml of venous blood was drawn from each participant. The
samples were collected in tubes containing ethylenediamine tetraacetic acid
(Sigma-Aldrich Corp., St Louis, MO, USA), immediately centrifuged to
separate the buffy coat containing polymorphonuclear cells and frozen at
201C for later DNA extraction.
The study protocol was approved by the ethics committee of Alagoas State
University. Written informed consent was obtained from each participant.
Experimental procedures on humans followed the ethical standards for human
experimentation that were established by the Declaration of Helsinki of 1975,
revised in 1983.
Genotyping
DNA was extracted from whole blood by the dodecyl trimethyl-ammonium
bromide/cetyl trimethyl-ammonium bromide (DTAB/CTAB, Sigma-Aldrich
Corp.) technique.22 Cytokine genotyping was carried out by the PCR
sequence-specific primer method, using the ‘Cytokine Genotyping Tray’
(One Lambda Inc., Canoga Park, CA, USA), according to the manufacturer’s
instructions. The polymorphisms analyzed in this study were TNF-a promoter
(308 G4A), IL6 promoter (174 G4C), IFN-g intron 1 (+874 A4T),
IL10 promoters (1082 A4G), (819 C4T) and (592 C4A) and TGF-b1
codon 10 (+869 T4C) and codon 25 (+915 G4C).
Following the kit’s manufacturer’s suggestion and literature recommenda-
tions,23–25 cytokine genotype and phenotype were grouped as follows: for the
TNF-a gene, the alleles were distributed as A/A and A/G (high) and G/G (low);
for the IL-6 gene, the groups were G/G and G/C (high) and C/C (low); for the
IL-10 gene, the alleles for each polymorphism were grouped as GCC/GCC
(high), GCC/ATA and GCC/ACC (intermediate) and ACC/ACC and ACC/ATA
(low); for the IFN-g gene, the alleles were distributed as T/T (high), T/A
(intermediate) and A/A (low); and for the TGF-b1 gene, the groups were T/T
G/G and T/C G/G (high), T/C G/C and C/C G/G (intermediate) and C/C G/C,
C/C C/C, T/T C/C and T/C C/C (low).
Statistical analysis
Sample size estimates were based on a reported 67% frequency of TNF-a
(308G) in the general population and a 43% frequency of TNF-a (308G) in
patients with increased susceptibility to E.26 Assuming a similar difference in
TNF-a (308G) frequencies between patients and controls, a two-tailed-a of
0.05 and 80% power, a sample size of 67 per group would be sufficient to detect
an association between this allele and E/PE. We selected this specific TNF-a
SNP for sample size calculation as it is the most frequently assessed in PE
studies.12–14,26,27
Hardy–Weinberg equilibrium tests were carried out by calculating the
expected frequencies of each genotype and comparing them with the observed
values. Arlequin software (Geneva, Switzerland) was used for these analyses.28
Single allelic and single genotype frequencies (obtained by direct count) were
analyzed by Fisher’s exact or w2 tests, with the level of significance set at
Pp0.05. Odds ratios and 95% confidence intervals were calculated.
RESULTS
The clinical characteristics of preeclamptic, eclamptic and control
women are presented in Table 1.
Linkage disequilibrium was detected between the three alleles of the
IL10 promoter, (1082 A4G), (819 C4T) and (592 C4A), and
between the two alleles of TGF-b1, codon 10 (+869 T4C) and codon
25 (+915 G4C) in all patient and control groups, confirming the
earlier findings.29
All SNPs in PE, E and in control patients were in Hardy–Weinberg
equilibrium. Genotyping data are presented in Table 2. Among the six
SNPs studied, we found no difference in genotype frequencies between
the groups.
We detected a higher frequency of IFN-g (+874 A) in eclamptic
patients in comparison with that in controls. (Fisher’s exact test: 70.3
vs. 57.8%, respectively; P¼0.02). There were no other significant
differences in allelic frequencies between eclamptic, preeclamptic
and control groups (Table 3).
DISCUSSION
We did not find an association between polymorphisms in genes,
TNF-a promoter (308 G4A), IL6 promoter (174 G4C), IFN-g
intron 1 (+874 A4T), IL10 promoters (1082 A4G), (819 C4T)
and (592 C4A) and TGF-b1 codon 10 (+869 T4C) and codon 25
(+915 G4C) and E or PE.
These results are in line with other publications,12,13,30–33 including
our earlier investigation.11 In that study, we evaluated cytokine gene
polymorphisms in preeclamptic and control women of three different
ethnic groups, and there was a significant association between PE and
IL-10 (1082-G/G) in white women.
The significantly higher frequency of IFN-g (+874 A) in eclamptic
patients in comparison with that in controls was unexpected and
could be because of chance. We did not detect a corresponding
expression in genotype frequency. This finding should be interpreted
with caution as it is the first time that this SNP is being investigated in
patients with E. This finding needs to be further investigated.
Table 1 Clinical characteristics of women with preeclampsia, eclampsia and controlsa
Variable Preeclampsia (n¼92) Eclampsia (n¼73) Controls (n¼101) (PE vs. C)b (E vs. C)b
Age (years) 23 (19–28) 18 (17–21) 26 (21–31) o0.0065 o0.0001
Prepregnancy BMI 23.43 (22.90–25.91) 24.27 (22.59–27.30) 23.02 (22.36–23.38) 0.14 0.32
SBP (mm Hg) 160 (150–180) 160 (140–180) 110 (110–120) o0.0001 o0.0001
DBP (mmHg) 110 (100–120) 110 (100–120) 70 (60–80) o0.0001 o0.0001
GA delivery (weeks) 37 (34–39) 37 (34–39) 39 (39–40) o0.0001 o0.0001
Birth weight (g) 2450 (1760–3100) 2500 (1890–2995) 3200 (2950–3970) o0.0001 o0.0001
Abbreviations: BMI, body mass index (kgm2); DBP, diastolic blood pressure; E, eclampsia; GA, gestational age; PE, preeclampsia; SBP, systolic blood pressure.
aData are expressed as median and interquartile ranges (25th–75th percentiles).
bMann–Whitney test.
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We selected SNPs in cytokine genes that are known to influence
cytokine production.23,24 However, the protocol used to measure
cytokine, the interactions between genes and environmental factors
involved in the activation of these genes may also affect cytokine
production. Therefore, the relationship between genotype and phe-
notype cannot always be clearly demonstrated.25
PE and E are considered as expressions of the same syndrome, with
E being the most severe form of PE. Although other studies have
investigated the relationship between PE and cytokine gene poly-
morphism, few have evaluated eclamptic patients. The PE syndrome is
a state of excessive inflammatory response. However, both excessive
Th1 (pro-inflammatory) and Th2 (anti-inflammatory) cytokine pro-
ductions have been associated with PE.3–5,34,35 Hence, although we
selected only patients with PE, we may have evaluated a heterogeneous
population, including women with different cytokine and genetic
profiles.
Polymorphisms in IL6, IL10, IFN-g and TGF-b1 genes in pre-
eclamptic patients have been investigated earlier, but most of these
studies involved the analysis of SNPs in the TNF-a gene. Several
polymorphisms in the promoter region of the TNF-a gene have been
described. Specifically, the TNF-a 308 G4A polymorphism has
been extensively evaluated because of functional significance, and
discordant results have been reported.11–14,27,36–38
Similarly, there is no consensus regarding cytokine production and
PE/E. There are studies indicating a consistent increase in TNF-a
production,39 others reporting that a part of these patients exhibit
Table 2 Genotype frequencies of the TNF-a promoter (308 G4A), IL6 promoter (174 G4C), IFN-c intron 1 (+874 A4T), IL10 promoter
(1082 A4G), (819 C4T), (592 C4A) and TGF-b1 codon 10 (+869 T4C), codon 25 (+915 G4C) polymorphisms in women with
preeclampsia, eclampsia and controlsa
Eclampsia Preeclampsia Controls
Gene (position) genotype N % P N % P N %
TNF-a (308 G4A) 64 88 97
GG 54 84.3 69 78.4 71 73.1
GA 9 14.2 0.24 16 18.2 0.49 24 24.7
AA 1 1.5 3 3.4 2 2.2
IFN-g (+874 T4A) 64 85 96
TT 6 9.3 7 8.2 18 18.8
TA 26 40.6 0.08 46 54.2 0.12 45 46.8
AA 32 50.1 32 37.6 33 34.4
IL-6 (174 G4) 60 82 93
GG 31 51.7 54 65.8 56 60.3
GC 21 35.0 0.30 24 29.3 0.72 31 33.3
CC 8 13.3 4 4.9 6 6.4
TGF-b (+10 T4C) 52 78 97
TT 13 25.0 22 28.3 25 25.8
TC 31 50.6 0.97 42 53.8 0.87 56 57.7
CC 8 15.4 14 17.9 16 16.5
TGF-b (+25 C4G) 52 78 97
GG 42 80.8 68 87.2 82 84.5
GC 10 19.2 0.72 10 12.8 0.77 15 15.5
CC 00 00 00
IL10 (1082 G4A) 62 88 95
GG 3 4.8 5 5.6 8 8.4
GA 30 48.4 0.67 36 40.9 0.35 46 48.4
AA 29 46.8 47 53.5 41 43.2
IL10 (819 C4T) 62 88 95
CC 21 33.8 39 44.3 40 42.1
CT 32 51.6 0.19 36 40.9 0.11 49 51.6
TT 9 14.6 13 14.8 6 6.3
IL10 (592 C4A) 62 88 95
CC 21 33.8 39 44.3 40 42.1
CA 32 51.6 0.19 36 40.9 0.11 49 51.6
AA 9 14.6 13 14.8 6 6.3
aw2 test, Fisher’s exact test.
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high TNF levels,40 whereas some investigators did not detect any
change in cytokine levels.41 These discrepancies have been reported for
almost all cytokines.42
These several conflicting findings could be because of heterogeneity
in study designs, definition of phenotype, SNP selection, population
diversity and sample size. These factors interfere with the interpreta-
tion of the results, especially in a complex disease such as PE.
Multiple mechanisms and mediators are involved in the develop-
ment of PE; therefore, this disorder can be associated with more than
one cytokine and with other non-cytokine genes.43,44 Moreover, gene–
gene interaction and environmental factors are likely to play a role in
determining an individual’s risk for a disease.29,45–47 These interac-
tions can be so important that they can obscure eventual associations
between gene polymorphisms and the disease and lead to discordant
results in different studies involving the same disorder.
To circumvent possible ethnic interference, we included only
Mulatto women from a single geographical location. This is the first
study that evaluates the relationship between six different cytokine
polymorphisms in preeclamptic and eclamptic patients and healthy
women without any obstetric or systemic disease. One of the limita-
tions of this study is the small sample size. However, the size was
sufficient to detect (with an 80% power) a possible association
between cytokine gene polymorphism and E/PE, in accordance with
earlier studies.26,27,48
These findings need to be replicated in future studies. The role of
these cytokine gene SNPs in PE/E has to be further investigated,
because they may be involved with etiology and not with susceptibility
to disease.
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